<Header>
<FileStats>
    <FileName>20161102_10-K-A_edgar_data_1369868_0001144204-16-131133_7.txt</FileName>
    <GrossFileSize>81094</GrossFileSize>
    <NetFileSize>24114</NetFileSize>
    <ASCII_Embedded_Chars>0</ASCII_Embedded_Chars>
    <HTML_Chars>49677</HTML_Chars>
    <XBRL_Chars>0</XBRL_Chars>
    <XML_Chars>0</XML_Chars>
    <N_Tables>2</N_Tables>
    <N_Exhibits>2</N_Exhibits>
</FileStats>
<SEC-Header>
0001144204-16-131133.hdr.sgml : 20161102
<ACCEPTANCE-DATETIME>20161102161527
ACCESSION NUMBER:		0001144204-16-131133
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20161102
DATE AS OF CHANGE:		20161102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			China Biologic Products, Inc.
		CENTRAL INDEX KEY:			0001369868
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				752308816
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34566
		FILM NUMBER:		161967993

	BUSINESS ADDRESS:	
		STREET 1:		18TH FL, JIALONG INTERNATIONALBUILDING
		STREET 2:		19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100125
		BUSINESS PHONE:		86-10-6598-3111

	MAIL ADDRESS:	
		STREET 1:		18TH FL, JIALONG INTERNATIONALBUILDING
		STREET 2:		19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100125

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRC Holdings, Inc.
		DATE OF NAME CHANGE:	20060721

</SEC-Header>
</Header>

 0001144204-16-131133.txt : 20161102

10-K/A
 1
 v451987_10ka.htm
 FORM 10-K/A

UNITED STATES  

  SECURITIES AND EXCHANGE COMMISSION  

 Washington, D.C. 20549 

FORM 10-K/A  

  (Amendment No. 1)  

ANNUAL REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the fiscal year ended:  December 31, 2014  

TRANSITION REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the transition period from ____________ to _____________ 

Commission File No. 001-34566 

CHINA BIOLOGIC PRODUCTS, INC.  

  (Exact name of registrant as specified
in its charter)  

Delaware   
       75-2308816    
 
       (State or other jurisdiction of incorporation or organization)   
       (I.R.S. Employer Identification No.)    

18th Floor, Jialong International Building,
19 Chaoyang Park Road   
 Chaoyang District, Beijing 100125   
 People s Republic of China   
 (Address of principal executive offices)  

(+86) 10-6598-3111   
 (Registrant s telephone number, including area code)  

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class   
       
       Name of each exchange on which registered    
 
      Common Stock, par value $0.0001 per share  
       
      NASDAQ Global Select Market   
 
      Preferred Share Purchase Rights  
       
      NASDAQ Global Select Market   

Securities registered pursuant to Section
12(g) of the Exchange Act: None 

Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes              
No   x  

Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes              
No   x  

Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes   x   No      

Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (  232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files) Yes   x          
No      

Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (  229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.      

Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of  large accelerated filer,   accelerated filer  and  smaller reporting company  in Rule 12b-2
of the Exchange Act. 

Large Accelerated Filer      
      Accelerated Filer   x   

Non-Accelerated
        Filer      
         (Do not check if a smaller reporting company)  
      Smaller reporting company       

Indicate
by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes              
No   x  

The aggregate market value of common stock
held by non-affiliates of the registrant, based upon the closing sale price on June 30, 2014 as reported on the NASDAQ Global Select
Market, was approximately $358 million. 

There were a total of 24,811,792 shares
of the registrant s common stock outstanding as of March 4, 2015. 

DOCUMENTS INCORPORATED BY REFERENCE  

Portions of the Registrant s Proxy
Statement for its 2015 Annual Meeting of Stockholders to be filed with the Commission within 120 days after the close of the Registrant s
fiscal year are incorporated by reference into Part III of this Annual Report on Form 10-K. 

Table
of Contents   

E xplanatory
    Note   
     3  
 
       ITEM 5. MARKET FOR REGISTRANT S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.   
     4  
 
       ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.   
     5  
 
       SIGNATURES   
     6  
 
       EXHIBIT INDEX   
     8  

2   

Explanatory
Note   

We are filing this Amendment No. 1 (this
 Amendment ) to our annual report on Form 10-K for the fiscal year ended December 31, 2014 (the  Original Form
10-K ), which was originally filed with the Securities and Exchange Commission on March 4, 2015, for the sole purpose of
revising information set forth in the section captioned  Securities Authorized for Issuance under Equity Compensation Plans 
under Item 5 provided pursuant to Item 201(d) of Regulation S-K. This Amendment does not affect the information in the other sections
under Item 5 of the Original Form 10-K. 

In addition, we are also filing new certifications
by our principal executive officer and principal financial officer as exhibits to this Amendment pursuant to Rule 13a-14(a) of
the Securities Exchange Act of 1934, as amended. Therefore, this Amendment also updates the list of exhibits under Item 15 of the
Original Form 10-K by incorporating such new certifications filed as Exhibits 31.1 and 31.2 hereto. We are not including certifications
pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being
filed with this Amendment. 

No other changes have been made to the
Original Form 10-K. This Amendment does not reflect events that have occurred after the filing of the Original Form 10-K, or modify
or update the disclosures presented therein, except to reflect the amendment described above. 

3   

PART II  

ITEM 5. MARKET FOR
REGISTRANT S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.  

Securities Authorized for Issuance under
Equity Compensation Plans   

The following table includes the information
as of December 31, 2014 for each category of our equity compensation plan: 

Plan category    
       Number of securities  to be issued upon  exercise of  outstanding options,  warrants and rights  (a)  (1)          
     Weighted-average  exercise price of  outstanding options,  warrants and rights  (b)       
     Number of securities  remaining available for  future issuance under  equity compensation  plans (excluding  securities reflected in  column (a))  (c)     
 
      Equity compensation plans approved by security holders (2)      
        1,432,454       
     $  10.16       
        1,488,545     
 
     Equity compensation plans not approved by security holders    
        -       
        -       
        -     
 
     Total    
        1,432,454       
     $  10.16       
        1,488,545     

(2)  Our board of directors adopted the 2008 Plan on May 9, 2008 and shortly thereafter sought and obtained
approval by written consent from the holders of a majority of our then outstanding shares, which we believed was effective approval
under the Delaware General Corporation Law. However, in response to an SEC comment in 2010, the disclosure in the foregoing table
was revised for presently unknown reasons to reflect that the 2008 Plan was not approved by our stockholders. We have recently
reviewed our records relating to the 2008 approval of the 2008 Plan. While the 2008 Plan was approved by stockholders holding a
majority of our stock acting by written consent, and therefore we believe that the 2008 Plan was approved, in connection with the
recent review of our records, we recognized that there may be some technical defects in the manner in which the approval was obtained
in 2008. We are in the process of collecting additional information and will continue our analysis of whether such stockholder
approval complied with all the technical requirements of Delaware law and will take appropriate steps in light of that assessment.   

The 2008 Plan provides for grants of stock
options, stock appreciation rights, performance units, restricted stock, restricted stock units and performance shares. A total
of five million shares of our common stock may be issued pursuant to the 2008 Plan. The exercise price per share for the shares
to be issued pursuant to an exercise of a stock option will be no less than the fair market value per share on the grant date,
except that, in the case of an incentive stock option granted to a person who holds more than 10% of the total combined voting
power of all classes of our stock or any of our subsidiaries, the exercise price will be no less than 110% of the fair market value
per share on the grant date. As of December 31, 2014, 552,125 shares of restricted stock and options to purchase 1,432,454 share
of our common stock were outstanding. No awards may be granted under the 2008 Plan after May 9, 2018, except that any award granted
before then may extend beyond that date. 

4   

PART IV  

ITEM 15. EXHIBITS,
FINANCIAL STATEMENT SCHEDULES.  

Exhibit List   

The list of exhibits in the Exhibit Index to this Report is
incorporated herein by reference. 

5   

SIGNATURES  

In accordance with section 13 or 15(d)
of the Securities Exchange Act of 1934, the registrant caused this Amendment No. 1 to the Annual Report on Form 10-K to be signed
on its behalf by the undersigned, thereto duly authorized individual. 

Date: November 2, 2016. 

CHINA BIOLOGIC PRODUCTS, INC.   

By:   /s/ David (Xiaoying) Gao                       

David (Xiaoying) Gao   
 Chief Executive Officer  

6   

POWER OF ATTORNEY  

KNOW ALL PERSONS BY THESE PRESENTS, that
each person whose signature appears below constitutes and appoints David (Xiaoying) Gao and Ming Yang, jointly and severally, as
his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name,
place and stead, in any and all capacities, to sign this Amendment No. 1 to the Annual Report on Form 10-K and to file the same,
with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto
said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary
to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their
substitute or substitutes, may lawfully do or cause to be done by virtue hereof. 

Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the
registrant in the capacities and on the dates indicated . 

Signature  
       
      Title  
      Date   

/s/ David (Xiaoying) Gao  
       
      Chairman and Chief Executive Officer  
      November 1, 2016   
 
      David (Xiaoying) Gao  
       
      (Principal Executive Officer)  

/s/ Ming Yang  
       
      Chief Financial Officer  
      November 1, 2016   
 
      Ming Yang  
       
      (Principal Financial and Accounting Officer )  

/s/ Sean Shao  
       
      Director  
      November 1, 2016   
 
      Sean Shao  

/s/ Joseph Chow  
       
      Director  
      November 1, 2016   
 
      Joseph Chow  

/s/ Yungang Lu  
       
      Director  
      November 1, 2016   
 
      Yungang Lu  

/s/ David Hui Li  
       
      Director  
      November 1, 2016   
 
      David Hui Li  

/s/ Wenfang Liu  
       
      Director  
      November 1, 2016   
 
      Wenfang Liu  

/s/ Albert (Wai Keung) Yeung  
       
      Director  
      November 1, 2016   
 
      Albert (Wai Keung) Yeung  

Director  

Zhijun Tong  

7   

EXHIBIT INDEX   

Exhibit No.   
       Description    
 
      2.1  
      Share Exchange Agreement between the Company, Logic Express Limited and the selling stockholders signatory thereto, dated as of July 18, 2006 (incorporated by reference to Exhibit 2 of the registration statement on Form SB-2 filed by the Company on September 5, 2007)   
 
      3.1  
      Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the quarterly report on Form 10-Q filed by the Company on August 9, 2012)   
 
      3.2  
      Second Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.2 of the quarterly report on Form 10-Q filed by the Company on August 9, 2012)   
 
      4.1  
      Form of Registration Rights Agreement, dated June 5, 2009 (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed by the Company on June 5, 2009)   
 
      4.2  
      Form of 3.8% Convertible Senior Secured Note due 2011 (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K filed by the Company on June 5, 2009)   
 
      4.3  
      Form of Warrant (incorporated by reference to Exhibit 4.3 of the Current Report on Form 8-K filed by the Company on June 5, 2009)   
 
      4.4  
      Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock of China Biologic Products, Inc. (incorporated by reference to Exhibit 3.1 of the registration form on Form 8-A12B filed by the Company on November 21, 2012)   
 
      10.1  
      China Biologic Products, Inc. 2008 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the Company on May 13, 2008)   
 
      10.2  
      Form of Stock Option Award Agreement of China Biologic Products, Inc. (incorporated by reference to  Exhibit 10.5 of the current report on Form 8-K filed by the Company on May 13, 2008)   
 
      10.3  
      Group Secondment Agreement, dated October 28, 2002, between Shandong Taibang Biological Products Co., Ltd. and the Shandong Institute (English Translation) (incorporated by reference to Exhibit 10.1 of the registration statement on Form SB-2/A filed by the Company on December 3, 2007)   
 
      10.4  
      Amended and Restated Joint Venture Agreement, between Logic Express Limited and the Shandong Institute, dated as of March 12, 2006 (English Translation) (incorporated by reference to Exhibit 10.2 of the registration statement on Form SB-2 filed by the Company on September 5, 2007)   
 
      10.5  
      Letter of Intent for Equity Transfer, between Logic Express Limited and the Shandong Institute, dated as of June 10, 2006 (English Translation) (incorporated by reference to Exhibit 10.3 of the registration statement on Form SB-2 filed by the Company on September 5, 2007)   
 
      10.6  
      Joint Venture and Cooperation Agreement between Mr. Fan Qingchun, Shandong Taibang Biological Products Co., Ltd. and Shaanxi Power Construction Corporation, dated September 12, 2008 (incorporated by reference to Exhibit 10.2 of the current report on Form 8-K filed by the Company on October 16, 2008)   
 
      10.7  
      Agreement on Equity Transfer, Acquisition, Joint Venture and Cooperation, among Shandong Taibang Biological Products Co., Ltd., Shaanxi Power Construction Corporation and Mr. Fan Qingchun, dated September 12, 2008 (incorporated by reference to Exhibit 10.3 of the current report on Form 8-K filed by the Company on October 16, 2008)   
 
      10.8  
      (Shareholder) Agreement among Shandong Taibang Biological Products Co., Ltd., Logic Express Limited and Biological Institute dated September 12, 2008 (incorporated by reference to Exhibit 10.4 of the current report on Form 8-K, filed by the Company on October 16, 2008)   
 
      10.9  
      Equity Transfer Agreement, dated September 26, 2008, among Logic Express Limited, Chongqing Dalin Biologic Technologies Co., Ltd. and certain shareholders of Chongqing Dalin Biologic Technologies Co., Ltd. (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the Company on October 2, 2008)   
 
      10.10  
      Equity Transfer Agreement, between Shandong Taibang Biological Products Co., Ltd. and Mr. Fan Qingchun, dated October 10, 2008 (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the Company on October 16, 2008)   
 
      10.11  
      Supplemental Agreement, dated November 3, 2008, among Logic Express Limited, Fan Shaowen, as representative of the shareholders of Chongqing Dalin Biologic Technologies Co., Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd. (English Translation) (incorporated by reference to Exhibit 10.2 of the current report on Form 8-K filed by the Company on November 7, 2008)   
 
      10.12  
      Second Supplemental Agreement, dated November 14, 2008, among Logic Express Limited, Fan Shaowen as representative of the shareholders of Chongqing Dalin Biologic Technologies Co., Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd. (English Translation) (incorporated by reference to exhibit 10.3 of the current report on Form 8-K filed by the Company on November 20, 2008)   

8   

10.13  
      Amended Equity Transfer Agreement, dated December 12, 2008, among Logic Express Limited, Chongqing Dalin Biologic Technologies Co., Ltd., and certain shareholders of Chongqing Dalin Biologic Technologies Co., Ltd. (English Translation) (incorporated by reference to exhibit 10.4 of the current report on Form 8-K filed by the Company on December 18, 2008)   
 
      10.14  
      Equity Transfer and Entrustment Agreement, dated April 6, 2009, among Logic Express, Shandong Taibang Biological Products Co., Ltd. and the Shandong Institute of Biological Products (English Translation) (incorporated by reference to Exhibit 10.6 of the current report on Form 8-K filed by the Company on April 13, 2009)   
 
      10.15  
      Asset Purchase Agreement, between Xia Jin An Tai Plasma Collection Co., Ltd. and Xia Jin County Plasma Collection Station, dated as of October 20, 2006 (English Translation) (incorporated by reference to Exhibit 10.15 of the registration statement on Form SB-2/A filed by the Company on December 3, 2007)   
 
      10.16  
      Asset Purchase Agreement, between Liao Cheng An Tai Plasma Collection Co., Ltd. and Yang Gu County Plasma Collection Station, dated as of November 3, 2006 (English Translation) (incorporated by reference to Exhibit 10.16 of the registration statement on Form SB-2/A filed by the Company on December 3, 2007)   
 
      10.17  
      Asset Purchase Agreement, between Qi He An Tai Plasma Collection Co., Ltd. and Qi He County Plasma Collection Station, dated as of November 9, 2006 (English Translation) (incorporated by reference to Exhibit 10.14 of the registration statement on Form SB-2/A filed by the Company on December 3, 2007)   
 
      10.18  
      Asset Purchase Agreement, between He Ze An Tai Plasma Collection Co., Ltd and Yun Cheng County Plasma Collection Station, dated as of December 15, 2006 (English Translation) (incorporated by reference to Exhibit 10.22 of the registration statement on Form SB-2/A filed by the Company on December 3, 2007)   
 
      10.19  
      Asset Purchase Agreement, between Zhang Qiu An Tai Plasma Collection Co., Ltd. and Zhang Qiu Plasma Collection Station, dated as of December 31, 2006 (English Translation) (incorporated by reference to Exhibit 10.12 of the registration statement on Form SB-2/A filed by the Company on December 3, 2007)   
 
      10.20  
      Asset Purchase Agreement, between Guang Xi Huan Jiang Missile Plasma Collection Co., Ltd. and Huan Jiang Maonan Autonomous County Plasma Collection Station, dated as of April 24, 2007 (English Translation) (incorporated by reference to Exhibit 10.13 of the registration statement on Form SB-2/A filed by the Company on December 3, 2007)   
 
      10.21  
      Asset Purchase Agreement, between Fang Cheng Plasma Collection Co., Ltd. and Fang Cheng Plasma Company, dated as of April 30, 2007 (English Translation) (incorporated by reference to Exhibit 10.21 of the registration statement on Form SB-2/A filed by the Company on December 3, 2007)   
 
      10.22  
      Asset Purchase Agreement, between Guang Xi Huan Jiang Missile Plasma Collection Co., Ltd. and Huan Jiang Maonan Autonomous County Plasma Collection Station, dated as of August 5, 2007 (English Translation) (incorporated by reference to Exhibit 10.13 of the registration statement on Form SB-2/A filed by the Company on December 3, 2007)   
 
      10.23  
      Trademark Licensing Agreement, dated as of February 27, 2007 (English Translation) (incorporated by reference to Exhibit 10.17 of the registration statement on Form SB-2/A filed by the Company on December 3, 2007)   
 
      10.24  
      Loan Agreement, dated as of November 30, 2006, among Shandong Taibang and the Shandong Institute and Logic Express (English Translation) (incorporated by reference to Exhibit 10.18 of the registration statement on Form SB-2/A filed by the Company on December 3, 2007)   
 
      10.25  
      Supplementary Agreement, dated as of September 1, 2007, among Shandong Taibang Biological Products Co., Ltd., the Shandong Institute and Logic Express Limited (English Translation) (incorporated by reference to Exhibit 10.19 of the registration statement on Form SB-2/A filed by the Company on December 3, 2007)   
 
      10.26  
      Employment Agreement, between David (Xiaoying) Gao and the Company, dated as of May 11, 2012 (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the Company on May 11, 2012)   
 
      10.27  
      Employment Agreement, between Ming Yang and the Company, dated August 31, 2012 (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the Company on September 7, 2012)   
 
      10.28  
      Form of Director s Employment Agreement (incorporated by reference to Exhibit 10.8 of the registration statement on Form SB-2 filed by the Company on September 5, 2007)   
 
      10.29  
      Form of Independent Director Agreement (incorporated by reference to Exhibit 10.1 of the current report on Form 8-K filed by the Company on July 30, 2008)   
 
      10.30  
      Form of Indemnity Agreement (incorporated by reference to Exhibit 10.2 of the current report on Form 8-K filed by the Company on July 30, 2008)   

9   

*Previously filed with our Annual Report
on Form 10-K for the year ended December 31, 2014, as filed on March 4, 2015. 

 **Previously furnished with our Annual
Report on Form 10-K for the year ended December 31, 2014, as filed on March 4, 2015. 

 ***Filed herewith. 

10   

<EX-31.1>
 2
 v451987_ex31-1.htm
 EXHIBIT 31.1

EXHIBIT 31.1   

CERTIFICATIONS  

I, David (Xiaoying) Gao, certify that: 

1.  I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of China Biologic Products, Inc.; and   

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report.   

Date: November 2 2016 

/s/ David (Xiaoying) Gao  

David (Xiaoying) Gao  

Chief Executive Officer   

(Principal Executive Officer)    

</EX-31.1>

<EX-31.2>
 3
 v451987_ex31-2.htm
 EXHIBIT 31.2

EXHIBIT 31.2   

CERTIFICATIONS  

I, Ming Yang, certify that: 

1.  I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of China Biologic Products, Inc.; and   

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report.   

Date: November 2, 2016 

/s/ Ming Yang  

Ming Yang  

Chief Financial Officer   

(Principal Financial and Accounting Officer)    

</EX-31.2>

